We have screened for CDKN2A germline mutations in 49 Jewish families with two or more cases of melanoma. The Val59Gly mutation, one of the three different alterations identified among these families, was also detected independently in two kindreds from France and one from Spain. The impact of the Val59Gly substitution on the function of the cyclin-dependent kinase inhibitor p16
We have screened for CDKN2A germline mutations in 49 Jewish families with two or more cases of melanoma. The Val59Gly mutation, one of the three different alterations identified among these families, was also detected independently in two kindreds from France and one from Spain. The impact of the Val59Gly substitution on the function of the cyclin-dependent kinase inhibitor p16 INK4a , a product of the CDKN2A gene, was assessed by protein -protein interaction and cell proliferation assays and related to potential structural alterations predicted by molecular modeling. Seven microsatellite markers in the vicinity of the CDKN2A gene were used to determine whether the mutation in these families is identical by descent, or represents a mutational hotspot in the CDKN2A gene. Our results show that the Val59Gly substitution impairs p16
INK4a function, and this dysfunction is consistent with structural predictions. All melanoma-affected individuals tested in the families under study harbor this mutation. Interestingly, the Israeli pedigree includes an affected individual who is homozygous for the Val59Gly mutation. A common haplotype of microsatellite markers has been demonstrated for mutation carriers in all four pedigrees. The Israeli pedigree and one of the French melanoma families are of Moroccan and Tunisian Jewish descent, respectively, and the other families originate from regions of France and Spain close to the Pyrenees. We conclude that the Val59Gly mutation is a major contributor to melanoma risk in the families under study and that it may derive from a single ancestral founder of Mediterranean (possibly Jewish) origin. European Journal of Human Genetics (2003) 11, 288 -296. doi:10.1038/sj.ejhg.5200961
Introduction
About 10% of melanoma patients come from families in which more than one individual has been affected by the disease. 1 A substantial proportion of these melanomaprone families show linkage to markers on chromosome 9p21 and most of them harbor a germline mutation in the CDKN2A gene. 1, 2 The CDKN2A gene is unusual in that it encodes two distinct proteins, p16 INK4a and p14
ARF
, by exploiting different first exons spliced to a common second exon that is translated in alternative reading frames. 3 The majority of the germline mutations associated with predisposition to malignant melanoma appear to impinge on the p16 INK4a product, a 156 amino-acid protein that functions as an inhibitor of the cyclin-dependent kinases CDK4 and CDK6. 4 In conjunction with their regulatory Dtype cyclins, these kinases orchestrate the passage of eucaryotic cells from quiescence to the so-called restriction point in the G1 phase of the cell cycle. The role of p16
INK4a
as a tumor suppressor is underscored by its inactivation by diverse mechanisms in a wide variety of human tumors. 3 In addition to an increased risk of melanoma, the existence of an increased risk of pancreatic cancer in a subset of families has become evident from epidemiological studies. 5 -10 An excess of breast cancer has also been described in two sets of families of Italian and Swedish origin. 9, 10 Dual predisposition to melanoma and neural system tumours was found associated with germline deletions on 9p21 chromosomal region containing sequences coding for p16 INK4a and p14 ARF or for p14 ARF only.
11,12
The search for mutations of the CDKN2A gene in numerous familial studies around the world (from America, Australia and Europe) shows that the frequency of CDKN2A mutations is about 20% on average but varies from 5 to 50% depending on the criteria for family selection.
2,7 -10,13 -20 Most CDKN2A mutations are missense mutations scattered throughout the coding sequences of exons 1a and 2, but there are also small intragenic insertions and deletions. 3 Several recurrent mutations present in melanoma-prone families from different continents have been shown to be founder mutations. Such are the Met53Ile mutation, 21 the 19 bp deletion in exon 2 22 and the most common mutation to date, Gly101Trp substitution, described in more than 30 families and sporadic multiple primary melanoma cases, mainly from Italy, France, the US and Spain. 23, 24 Recently, a new recurrent mutation, CDKN2A Val59Gly, was found in four different families: one Israeli of Moroccan Jewish ancestry, two French (one of Tunisian Jewish ancestry and another without known Jewish roots) and a Spanish melanoma pedigree. 18, 19, 25 In this report, we provide evidence for functional impairment, association with the disease phenotype and a single genetic origin of the Val59Gly mutation.
Materials and methods

Melanoma families
Melanoma families under study were recruited in Israel, France and Spain as previously described.
-20
Mutation detection
Mutation detection by PCR -single strand polymorphism conformation (PCR -SSCP) analysis and direct DNA sequencing was carried out as previously described. 20 Genomic DNA was extracted from whole-blood samples and DNA fragments containing p16 gene exon 1, exon 2 (fragments 2A, 2B and 2C) and exon 3, with respective intron/exon junctions and the untranslated 3 0 portion were amplified using 33 P labeled nucleotides, and electrophoretically separated for SSCP analysis. Variant SSCP bands were purified, reamplified and sequenced. Sequence alterations were confirmed by restriction analysis.
Molecular modeling
The impact of the Val59Gly substitution on the 3D structure of p16 protein was evaluated as described by us earlier. 20 
Microsatellite marker analysis
Sequences of the forward and reverse primers for the D9S162, D9S1749, D9S974, D9S942, D9S1748, D9S1604 and D9S171 microsatellite markers were obtained from GenBank Database. PCR reactions using genomic DNA of individuals from all four melanoma families were performed as described. 20 PCR products were separated on 6%
polyacrylamide -urea sequencing gels and visualized by autoradiography. Microsatellite alleles observed in the tested panel of DNA samples were arbitrarily numbered starting with the band of highest molecular weight.
Results
Structural and functional characterization of the Val59Gly mutation
We have used molecular modeling to predict the likely impact of p16 INK4a mutations on its functional interactions with CDK4 and CDK6, based on the published crystal structure of the p16 -CDK6 complex. 27, 28 Val59 occupies a position in the hydrophobic core of p16 INK4a second ankyrin repeat (Figure 1a ). Our analysis suggests that substitution of Gly at this position will induce a distortion of the canonical conformation of the alpha-helix 30 and a disruption of the hydrophobic interface formed by Val25, Val28, Leu31, Leu32, Val59, Ala60, Leu62 and Leu63. These two factors, the low tendency of Gly residues to be part of an alpha-helix and the distortion of the hydrophobic core, are likely to have a pronounced effect on the general folding of p16 INK4a , including a change in the relative positions of two alpha-helices formed by residues 25 -33 and 57 -65. This in turn will change and potentially impair the formation of the conserved H-bond network between the first and the second ankyrin repeats of p16 INK4a and CDK6 ( Figure 1b) . Thus, both the stability of the p16
INK4a molecule and its binding to CDK6 will apparently be compromised by the Val59Gly mutation.
To evaluate the functional impact of the Vla59Gly substitution, the T to G change was introduced into the INK4a variants with endogenous CDK4 and CDK6 in human diploid fibroblasts. TIG-er cells (42 PDs) were infected with recombinant ecotropic retroviruses encoding 2HA-tagged p16
INK4a variants and selected in 2.5 mg/ml puromycin. At 7 days after infection, lysates were prepared in NP40 lysis buffer and 300 mg protein samples were used for immunoprecipitation with antibodies against CDK4 (H-22, Santa Cruz) or against CDK6 (C-21, Santa Cruz). Immunoprecipitated proteins were separated by SDS-PAGE in a 12% polyacrylamide gel and immunoblotted with JC8 antibody against the amino-terminal region of p16 INK4a variant on proliferation of human diploid fibroblasts. TIG-er cells were infected with recombinant retroviruses, as above, and 7 days after selection, cells were transferred into 24-well plates (5 Â 103 cells per well) and followed for 10 days. For each time point, cells were fixed in 10% formaldehyde and viable cells stained with crystal violet. Relative numbers of cells were determined by measurements of the optical density at 590 nm. Each time point was determined in triplicate and the averages plotted.
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INK4a by site-directed mutagenesis, and the variant protein was tested for its ability to interact with CDK4 and CDK6 in vitro and in vivo. Although the Val59Gly variant retained the ability to bind to CDK4 and CDK6 in vitro (Figure 2a) , it appeared to have reduced affinity for both CDK4 and CDK6 when expressed in primary human diploid fibroblasts (HDFs) by retroviral transduction (Figure 2b) 
Melanoma families carrying the Val59Gly substitution
The pedigrees of four melanoma-prone families are depicted in Figure 3 . Figure 3a shows the extended Israeli family of Moroccan Jewish origin that formed the impetus for this study. The proband, the female subject designated 8 on the pedigree, was diagnosed with malignant melanoma (MM) on her cheek at the age of 40 years. Her brother, designated 10, developed MM on his chin at the age of 36 years. The parents of the MM-affected individuals were of consanguineous marriage, as were their grandparents. The two individuals who developed MM at the time of this study were born and raised in Israel, while their parents and others of that generation were born and lived most of their life in Morocco. This Jewish family originates from the Antifa village, near Marakesh, in central Morocco. No other cancers were reported in this family. A total of 11 individuals indicated in Figure 3a were screened for the presence of the Val59Gly CDKN2A germline mutation. Individuals 1, 2, 3, 7 and 8 were found to carry the mutation in a heterozygous state. The affected male, designated 10 on the pedigree, was found to carry the same mutation in a homozygous state. His mother, designated 6, is apparently an obligate carrier. Individuals 4, 5, 9, 11 and 12 were found to have a wild-type CDKN2A genotype. Figure 3b shows the pedigree of the French melanoma family. This family is of Tunisian-Jewish descent. The proband, the female subject designated 1 in the pedigree, was first diagnosed with MM at the age of 27 years. She had a second primary at age 45 years and was genotyped as a carrier of the Val59Gly mutation. This female subject had dysplastic nevus syndrome, pale phototype I skin and red hair color. Her brother, designated 3, had MM at the age of 36 years. Another brother, designated 2, developed glioblastoma at the age of 62 years, in line with previous reports of gliomas being possibly associated with CDKN2A germline mutations. 11, 12 A sister of the proband, designated 4 on the pedigree, was afflicted by osteosarcoma at the age of 26 years. The unaffected sister, designated 5 on the pedigree, was tested and found to be a noncarrier of the Val59Gly mutation. Figure 3c depicts another French melanoma family with three MM-affected individuals. The proband, the female subject designated 1, developed MM at the age of 47 years, while her sister, designated 2, was diagnosed at the age of 35 years. After 2 years later, individual 2 developed lung melanoma metastasis and 2 years after that, brain metastasis. She died at the age of 40 years. Their brother, designated 7, had three primary melanomas, at ages 45, 49 and 51 years, respectively. The individual designated 6 developed lung carcinoma at the age of 43 years, being a moderate smoker. Individuals 1, 7 and 8 were identified as Val59Gly mutation carriers, while those designated 3, 4 and 5 were found to have a wild-type CDKN2A genotype. This family comes from the Languedoc-Roussillon region of south-west France, near the Pyrenees mountains, and is not aware of any Jewish ancestry. Figure 3d shows the Spanish melanoma family with three melanoma-afflicted individuals. The proband, the male designated 1, was first diagnosed with MM at the age of 66 years. He had two more melanoma primaries 10 years later. He also had dysplastic nevus syndrome. This patient died of cardiac pathology at the age of 77 years. The proband's son, designated 4, developed MM at the age of 36 years. A female subject in this pedigree, designated 3, was also affected by MM. Individual 2 had an unidentified neoplasm, individual 5 had colon cancer and squamous cell carcinoma, and individual 6 was reported to have an unidentified neoplasm. The proband was found to carry the Val59Gly mutation, but individual 5, with colon cancer and squamous cell carcinoma, had a wild-type CDKN2A genotype. This Spanish melanoma family has resided for several generations in the Barcelona area, on the southern side of the Pyrenees, and is also not aware of any Jewish ancestry.
Evidence for a single origin of the Val59Gly mutation in the Israeli, French and Spanish families To determine whether the mutation in the four apparently unrelated MM families described here is identical by descent, or represents a mutational hotspot in the CDKN2A gene, we have performed haplotype analysis in mutation carriers identified in these families. Seven microsatellite markers in vicinity of the CDKN2A gene used for this analysis are shown in Figure 4a . Our results indicate that mutation carriers of the Israeli, French and Spanish families possess a common haplotype for the closest four markers, D9S974, D9S942, D9S1748 and D9S1604, to the CDKN2A gene. The data are summarized in Table 1 and Figure 4b shows representative data obtained for D9S942 and D9S974.
Discussion
The impact of the Val59Gly substitution on the structure of p16 INK4a , as deduced by molecular modeling, strongly suggested that both the stability of the p16 INK4a molecule and its binding to CDK4 and CDK6 will be compromised by the mutation (Figure 1 ). The functional analyses indicated that Val59Gly has a moderate effect on the binding of p16 INK4a to CDK4 and CDK6, consistent with the results of the in vivo proliferation assays in human diploid fibroblasts (Figure 2 ). Although the Val59Gly variant retained the ability to bind to CDK4 and CDK6 in vitro at 301C, a more subtle impact on the protein structure, as demonstrated for some temperature-sensitive mutant proteins, 29 cannot be excluded. Together with the finding that all MM-affected individuals tested harbor the Val59Gly mutation, these results establish the Val59Gly mutation as a major contributor to melanoma risk in the families under study. A remarkable feature of the Israeli family is that it includes an individual who is homozygous for the Val59Gly mutation. To our knowledge, the only other example of homozygous defect in CDKN2A occurred in the Dutch melanoma kindred with a germline deletion within exon 2. 22 Both in the Dutch pedigree and in the Moroccan-Jewish pedigree described here, the clinical presentation of the disease in homozygous individuals was not significantly different from those bearing heterozygous germline mutations. Recently, by using primary fibroblasts isolated from a homozygous individual from the Dutch melanoma kindred and a double heterozygous melanoma patient, it was shown that lack of functional p16 INK4a but not of p14 ARF causes resistance of these cells to oncogenic RAS-induced replication arrest. 31, 32 Fibroblasts and other cell types derived from individuals of the Moroccan-Jewish family, who are homozygous or heterozygous for the Val59Gly mutation, could be of considerable value for further studies on the quantitative role of p16 INK4a in sensitivity to transformation, replicative senescence and other aspects of cell physiology relevant to development of malignant tumors. So far, only four families worldwide were reported to possess the Val59Gly mutation. The Israeli melanoma family represents a large pedigree of Moroccan-Jewish origin. One of the French melanoma families is of Tunisian-Jewish descent. Etymological and historical records provide evidence that Jews with the family names identical to these two families were indeed residing in Morocco in a Jewish community at Fez, dating as early as the 16th and 17th centuries. 33 The other two families, residing on opposite sides of the Pyrenees mountain ridge 34 Since many Jews in Spain converted to Christianity in and around the 15th century, it is not surprising to find similar haplotypes in Jewish and nonJewish families 500 years later. Identification of additional families with the Val59Gly mutation and characterization of the associated haplotypes might allow estimation of the age of the Val59Gly mutation with reasonable precision and thus help in establishing its origins. Nevertheless, our results together with that reported previously 21 -24 provide further evidence demonstrating common founders for most of the recurrent mutations in the CDKN2A gene. The identification of a founder mutation in a defined geographic area, in this case the Mediterranean basin, can provide an opportunity to study disease penetrance, 35 the 
ND ND a DNA sample designation refers to individuals in the pedigrees presented in Figure 3 . The observed alleles were numbered starting with the band of highest molecular weight. See Figure 4b illustrating analysis of markers D9S974 and D9S942. ND: not determined. The presumed common haplotype associated with the V59G mutation is shown in bold.
